GILEAD SCIENCES, INC. (GILD) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$10.39B; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income $2.59B; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income $3.33B; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income $2.47B; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$10.39B | (m) | $7.80B | (m) | $140.00M* | $3.57B* | $1.58B | (m) | $1.92B | $242.00M |
| 2026-03-31 | Reported | (m) | $2.59B | (m) | $6.96B | (m) | $117.00M | $2.54B | $1.45B | (m) | $1.45B | $559.00M |
| 2025-09-30 | Reported | (m) | $3.33B | (m) | $7.77B | (m) | $147.00M* | $4.11B* | $1.57B | (m) | $1.36B | $589.00M |
| 2025-06-30 | Reported | (m) | $2.47B | (m) | $7.08B | (m) | $107.00M* | $827.00M* | $1.50B | (m) | $1.36B | $468.00M |
| 2025-03-31 | Reported | (m) | $2.24B | (m) | $6.67B | (m) | $104.00M | $1.76B | $1.54B | (m) | $1.26B | $334.00M |
| 2024-09-30 | Reported | (m) | $888.00M | (m) | $7.54B | (m) | $141.00M* | $4.31B* | $1.57B | (m) | $1.43B | -$297.00M |
| 2024-06-30 | Reported | (m) | $2.64B | (m) | $6.95B | (m) | $130.00M* | $1.32B* | $1.54B | (m) | $1.38B | $438.00M |
| 2024-03-31 | Reported | (m) | -$4.32B | (m) | $6.69B | (m) | $105.00M | $2.22B | $1.55B | (m) | $1.38B | -$315.00M |
| 2023-09-30 | Reported | (m) | $2.62B | (m) | $7.05B | (m) | $122.00M* | $1.75B* | $1.56B | (m) | $1.31B | $146.00M |
| 2023-06-30 | Reported | (m) | $1.67B | (m) | $6.60B | (m) | $139.00M* | $2.34B* | $1.44B | (m) | $1.85B | $549.00M |
| 2023-03-31 | Reported | (m) | $1.71B | (m) | $6.35B | (m) | $109.00M | $1.74B | $1.40B | (m) | $1.32B | $316.00M |
| 2022-09-30 | Reported | (m) | $2.84B | (m) | $7.04B | (m) | $157.00M* | $2.86B* | $1.40B | (m) | $1.21B | $646.00M |
| 2022-06-30 | Reported | (m) | $2.03B | (m) | $6.26B | (m) | $143.00M* | $1.80B* | $1.44B | (m) | $1.36B | $368.00M |
| 2022-03-31 | Reported | (m) | $197.00M | (m) | $6.59B | (m) | $247.00M | $1.84B | $1.42B | (m) | $1.08B | -$164.00M |
| 2021-09-30 | Reported | (m) | $3.84B | (m) | $7.42B | (m) | $139.00M* | $3.25B* | $1.22B | (m) | $1.19B | $852.00M |
| 2021-06-30 | Reported | (m) | $2.25B | (m) | $6.22B | (m) | $119.00M* | $2.32B* | $1.39B | (m) | $1.35B | $300.00M |
| 2021-03-31 | Reported | (m) | $2.89B | (m) | $6.42B | (m) | $165.00M | $2.61B | $1.36B | (m) | $1.05B | $542.00M |
| 2020-09-30 | Reported | (m) | $2.00B | (m) | $6.58B | (m) | $155.00M* | $2.25B* | $1.14B | (m) | $1.11B | $472.00M |
| 2020-06-30 | Reported | (m) | -$2.98B | (m) | $5.14B | (m) | $143.00M* | $2.57B* | $1.06B | (m) | $1.24B | $373.00M |
| 2020-03-31 | Reported | (m) | $2.40B | (m) | $5.55B | (m) | $171.00M | $1.44B | $969.00M | $1.10B | $1.08B | $465.00M |
| 2019-09-30 | Reported | (m) | -$1.47B | (m) | $5.60B | (m) | $200.00M* | $2.65B* | $1.03B | $4.99B | $1.05B | -$333.00M |
| 2019-06-30 | Reported | (m) | $2.43B | (m) | $5.68B | (m) | $185.00M* | $2.34B* | $1.00B | $1.16B | $1.09B | $535.00M |
| 2019-03-31 | Reported | (m) | $2.24B | (m) | $5.28B | (m) | $237.00M | $1.58B | $957.00M | $1.06B | $1.03B | $382.00M |
| 2018-09-30 | Reported | (m) | $2.62B | (m) | $5.60B | (m) | $167.00M* | $2.21B* | $1.09B | $939.00M | $948.00M | $565.00M |
| 2018-06-30 | Reported | (m) | $2.28B | (m) | $5.65B | (m) | $297.00M* | $1.57B* | $1.20B | $1.19B | $980.00M | $267.00M |
| 2018-03-31 | Reported | (m) | $2.15B | (m) | $5.09B | (m) | $212.00M | $2.27B | $1.00B | $937.00M | $997.00M | $494.00M |
| 2017-09-30 | Reported | (m) | $3.81B | (m) | (m) | (m) | $129.00M* | $2.69B* | $1.03B | $789.00M | $879.00M | $959.00M |
| 2017-06-30 | Reported | (m) | $4.25B | (m) | (m) | (m) | $123.00M* | $3.53B* | $1.13B | $864.00M | $897.00M | $1.05B |
| 2017-03-31 | Reported | (m) | $3.77B | (m) | (m) | (m) | $118.00M | $2.92B | (m) | $931.00M | $850.00M | $918.00M |
| 2016-09-30 | Reported | (m) | $4.40B | (m) | (m) | (m) | $198.00M* | $4.39B* | (m) | $1.14B | $831.00M | $951.00M |
| 2016-06-30 | Reported | (m) | $4.54B | (m) | (m) | (m) | $204.00M* | $4.99B* | (m) | $1.48B | $890.00M | $902.00M |
| 2016-03-31 | Reported | (m) | $4.65B | (m) | (m) | (m) | $177.00M | $4.13B | (m) | $1.26B | $685.00M | $935.00M |
| 2015-09-30 | Reported | (m) | $5.58B | (m) | (m) | (m) | (m) | $4.10B* | (m) | $743.00M | $903.00M | $880.00M |
| 2015-06-30 | Reported | (m) | $5.62B | (m) | (m) | (m) | (m) | $5.66B* | (m) | $818.00M | $812.00M | $1.01B |
| 2015-03-31 | Reported | (m) | $5.37B | (m) | (m) | (m) | (m) | $5.70B | (m) | $696.00M | $645.00M | $907.00M |
| 2014-09-30 | Reported | (m) | $3.48B | (m) | (m) | (m) | (m) | $4.04B* | (m) | $630.00M | $945.00M | $647.00M |
| 2014-06-30 | Reported | (m) | $4.41B | (m) | (m) | (m) | (m) | $4.18B* | (m) | $584.00M | $614.00M | $656.00M |
| 2014-03-31 | Reported | (m) | $3.04B | (m) | (m) | (m) | (m) | $1.57B | (m) | $595.00M | $548.00M | $726.00M |
| 2013-09-30 | Reported | (m) | $1.15B | (m) | (m) | (m) | (m) | $753.10M* | (m) | $546.24M | $406.86M | $294.47M |
| 2013-06-30 | Reported | (m) | $1.15B | (m) | (m) | (m) | (m) | $953.00M* | (m) | $523.90M | $404.99M | $307.98M |
| 2013-03-31 | Reported | (m) | $1.03B | (m) | (m) | (m) | (m) | $672.10M | (m) | $497.63M | $374.30M | $222.44M |
| 2012-09-30 | Reported | (m) | $1.04B | (m) | (m) | (m) | (m) | $745.37M* | (m) | $465.83M | $319.58M | $280.05M |
| 2012-06-30 | Reported | (m) | $1.06B | (m) | (m) | (m) | (m) | $1.29B* | (m) | $396.24M | $332.50M | $263.52M |
| 2012-03-31 | Reported | (m) | $800.19M | (m) | (m) | (m) | (m) | $452.97M | (m) | $458.21M | $443.12M | $231.30M |
| 2011-09-30 | Reported | (m) | $1.00B | (m) | (m) | (m) | (m) | $897.11M* | (m) | (m) | $295.93M | $237.45M |
| 2011-06-30 | Reported | (m) | $1.02B | (m) | (m) | (m) | (m) | $943.25M* | (m) | (m) | $304.27M | $240.13M |
| 2011-03-31 | Reported | (m) | $901.97M | (m) | (m) | (m) | (m) | $820.54M | (m) | (m) | $295.57M | $227.28M |
| 2010-09-30 | Reported | (m) | $979.07M | (m) | (m) | (m) | (m) | $739.42M* | (m) | (m) | $250.56M | $258.88M |
| 2010-06-30 | Reported | (m) | $992.63M | (m) | (m) | (m) | (m) | $699.08M* | (m) | (m) | $248.01M | $284.02M |
| 2010-03-31 | Reported | (m) | $1.16B | (m) | (m) | (m) | (m) | $670.57M | (m) | (m) | $265.62M | $307.74M |
| 2009-09-30 | Reported | (m) | $894.41M | (m) | (m) | (m) | (m) | $860.53M* | (m) | (m) | $227.43M | $220.73M |
| 2009-06-30 | Reported | (m) | $761.06M | (m) | (m) | (m) | (m) | $622.92M* | (m) | (m) | $261.41M | $186.35M |
| 2009-03-31 | Reported | (m) | $808.32M | (m) | (m) | (m) | (m) | $641.33M | (m) | (m) | $203.95M | $209.23M |
| 2008-09-30 | Reported | (m) | $693.83M | (m) | (m) | (m) | (m) | $518.52M* | (m) | (m) | $189.19M | $187.40M |
| 2008-06-30 | Reported | (m) | $605.51M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $219.53M | $170.49M |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | $10.02B | (m) | $29.44B | (m) | $563.00M | $10.02B | $6.23B | (m) | $5.77B | $1.29B |
| 2024-12-31 | Reported | (m) | $1.66B | (m) | $28.75B | (m) | $523.00M | $10.83B | $6.25B | (m) | $6.09B | $211.00M |
| 2023-12-31 | Reported | (m) | $7.61B | (m) | $27.12B | (m) | $585.00M | $8.01B | $6.50B | (m) | $6.09B | $1.25B |
| 2022-12-31 | Reported | (m) | $7.33B | (m) | $27.28B | (m) | $728.00M | $9.07B | $5.66B | (m) | $5.67B | $1.25B |
| 2021-12-31 | Reported | (m) | $9.92B | (m) | $27.30B | (m) | $579.00M | $11.38B | $6.60B | (m) | $5.25B | $2.08B |
| 2020-12-31 | Reported | (m) | $4.07B | (m) | $24.69B | (m) | $650.00M | $8.17B | $4.57B | (m) | $5.15B | $1.58B |
| 2019-12-31 | Reported | (m) | $4.29B | (m) | $22.45B | (m) | $825.00M | $9.14B | $4.67B | $9.11B | $4.38B | -$204.00M |
| 2018-12-31 | Reported | (m) | $8.20B | (m) | $22.13B | (m) | $924.00M | $8.40B | $4.85B | $5.02B | $4.06B | $2.34B |
| 2017-12-31 | Reported | (m) | $14.12B | (m) | $26.11B | (m) | (m) | $11.90B | $4.37B | $3.73B | $3.88B | $8.88B |
| 2016-12-31 | Reported | (m) | $17.63B | (m) | $30.39B | (m) | (m) | $17.05B | $4.26B | $5.10B | $3.40B | $3.61B |
| 2015-12-31 | Reported | (m) | $22.19B | (m) | (m) | (m) | (m) | $21.25B | (m) | $3.01B | $3.43B | $3.55B |
| 2014-12-31 | Reported | (m) | $15.27B | (m) | (m) | (m) | (m) | $12.82B | (m) | $2.85B | $2.98B | $2.80B |
| 2013-12-31 | Reported | (m) | $4.52B | (m) | (m) | (m) | $134.00M | $3.10B | (m) | $2.12B | $1.70B | $1.15B |
| 2012-12-31 | Reported | (m) | $4.01B | (m) | (m) | (m) | (m) | $3.19B | (m) | $1.76B | $1.46B | $1.04B |
| 2011-12-31 | Reported | (m) | $3.79B | (m) | (m) | (m) | (m) | $3.64B | (m) | $1.23B | $1.24B | $861.95M |
| 2010-12-31 | Reported | (m) | $3.96B | (m) | (m) | (m) | (m) | $2.83B | (m) | (m) | $1.04B | $1.02B |
| 2009-12-31 | Reported | (m) | $3.53B | (m) | (m) | (m) | (m) | $3.08B | (m) | (m) | $946.69M | $876.36M |
| 2008-12-31 | Reported | (m) | $2.68B | (m) | (m) | (m) | (m) | $2.14B | (m) | (m) | $797.34M | $702.36M |
| 2007-12-31 | Reported | (m) | $2.16B | (m) | (m) | (m) | (m) | $1.67B | (m) | (m) | $705.74M | $635.36M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |